Table 3 OR and 95% CI values of different inflammatory parameters used as prognostic indicators for PC submitted to radiotherapy

Systemic inflammation NLR

[53]

Phase II on radiotherapy as primary treatment

NLR and clinical progression free survival or overall survival

3.09 (1.64–5.82)

<0.001

2.16 (1.17–3.99)

0.013

Systemic inflammation PLR

[55]

Phase II study on radiotherapy as primary treatment

PLR and metastasis free survival or cancer specific survival or overall survival

2.24 (1.06–4.76)

0.036

3.99 (1.19–13.4)

0.025

1.87 (1.02–3.42)

0.044

SNP in RNASEL

[56]

Phase II study on radiotherapy as primary treatment

SNP of rs12757998 and biochemical recurrence

0.60 (0.40–0.89)

0.02

Systemic inflammation CRP

[57]

Phase II study on radiotherapy as primary treatment

CRP and cancer specific survival or overall survival

3.36 (1.42–7.91)

0.006

3.24 (1.84–5.71)

<0.001